ASO Author Reflections: Oncological Outcomes of Adding Induction Chemotherapy Before Chemoradiotherapy with Total Mesorectal Excision and Selective Lateral Lymph Node Dissection in Patients with Poor-Risk, Locally Advanced Rectal Cancer

Tomohiro Yamaguchi¹, Takashi Akiyoshi², Tsuyoshi Konishi^{2

3}

Affiliations

¹ Department of Gastroenterological Surgery, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan. tyamaguchi-ncd@umin.ac.jp.
² Department of Gastroenterological Surgery, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
³ Department of Colon and Rectal Surgery, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.

Comment

Tomohiro Yamaguchi et al. Ann Surg Oncol. 2023 Aug.

. 2023 Aug;30(8):4725-4726.

doi: 10.1245/s10434-023-13462-y. Epub 2023 Apr 10.

Tomohiro Yamaguchi¹, Takashi Akiyoshi², Tsuyoshi Konishi^{2

3}

¹ Department of Gastroenterological Surgery, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan. tyamaguchi-ncd@umin.ac.jp.
² Department of Gastroenterological Surgery, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
³ Department of Colon and Rectal Surgery, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.

No abstract available

Comment on

Adding Induction Chemotherapy Before Chemoradiotherapy with Total Mesorectal Excision and Selective Lateral Lymph Node Dissection for Patients with Poor-Risk, Locally Advanced, Mid-to-Low Rectal Cancer May Improve Oncologic Outcomes: A Propensity Score-Matched Analysis.
Yamaguchi T, Akiyoshi T, Fukunaga Y, Sakamoto T, Mukai T, Hiyoshi Y, Nagasaki T, Taguchi S, Chino A, Shinozaki E, Yamaguchi K, Konishi T. Yamaguchi T, et al. Ann Surg Oncol. 2023 Aug;30(8):4716-4724. doi: 10.1245/s10434-023-13458-8. Epub 2023 Apr 9. Ann Surg Oncol. 2023. PMID: 37032405

1. Petrelli F, Trevisan F, Cabiddu M, et al. Total neoadjuvant therapy in rectal cancer: a systematic review and meta-analysis of treatment outcomes. Ann Surg. 2020;271:440–8. - DOI - PubMed
1. Bahadoer RR, Dijkstra EA, van Etten B, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:29–42. - DOI - PubMed
1. Conroy T, Bosset JF, Etienne PL, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:702–15. - DOI - PubMed
1. Garcia-Aguilar J, Patil S, Gollub MJ, et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol. 2022;40:2546–56. - DOI - PubMed
1. Yamaguchi T, Akiyoshi T, Konishi T, et al. Adding induction chemotherapy before chemoradiotherapy with total mesorectal excision and selective lateral lymph node dissection in patients with poor-risk, locally advanced, mid-to-low rectal cancer may improve oncological outcomes: a propensity score-matched analysis. Ann Surg Oncol. 2023. https://doi.org/10.1245/s10434-023-13458-8 . - DOI - PubMed